Gene · 22918
Papers1,470
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,470
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Complement expression profiles in human glomerular mesangial cells, endothelial cells, podocytes and proximal tubular epithelial cells. | Front Immunol | 2026 | 42746023 | PubTator, text mining | PubMed |
| Micro-vascularized multicellular pancreatic ductal adenocarcinoma (PDAC) spheroid: A novel 3D PDAC research model. | Transl Res | 2026 | 42679994 | PubTator, text mining | PubMed |
| Integrative Genome-Wide Association Study with eQTL Combined with Transcriptome Analysis Reveals SLC18A1 as a Novel Biomarker for Small Cell Lung Cancer. | Curr Med Chem | 2026 | 42634329 | PubTator, text mining | PubMed |
| Integrating Genetic Modifier Genotype With Serum Proteomics in Duchenne Muscular Dystrophy Clinical Trials Links LTBP4 Genetic Modifier to IL-23/CD93 Pathways in Muscle. | Am J Med Genet A | 2026 | 42613652 | PubTator, text mining | PubMed |
| IL-17D reprograms CD93+ antigen-presenting cells in the glioblastoma microenvironment. | Cell Mol Immunol | 2026 | 42595853 | PubTator, text mining | PubMed |
| Generative AI-driven de novo design of high-affinity, epitope-specific antibodies targeting the CD93-IGFBP7 axis for cancer immunotherapy. | Antib Ther | 2026 | 42592032 | PubTator, text mining | PubMed |
| Effects of high CD93 expression on tumor growth and angiogenesis in gastric adenocarcinoma. | PLoS One | 2026 | 42585231 | PubTator, text mining | PubMed |
| A scheme to tackle the dilemma from hepatoma cells under doxorubicin-resistant surroundings: a brightness or a silhouette. | Artif Cells Nanomed Biotechnol | 2026 | 42482449 | PubTator, text mining | PubMed |
| CD93-An emerging vascular target in cancer therapy. | Br J Pharmacol | 2026 | 42438215 | PubTator, text mining | PubMed |
| Integrated single-cell RNA sequencing and Bulk-RNA technologies reveal the immunological characteristics of lactylation related-genes in glioblastoma. | PLoS One | 2026 | 42361107 | PubTator, text mining | PubMed |
| Rational design of hammerhead ribozymes as CD93 silencing tools for vascular diseases. | Mol Ther Nucleic Acids | 2026 | 42293250 | PubTator, text mining | PubMed |
| C1q-CD44 interactions regulate microglial phagocytosis, proliferation, and migration. | J Neuroinflammation | 2026 | 42286716 | PubTator, text mining | PubMed |
| Multicolor detection of chronic myeloid leukemia stem cells, including novel marker CD69, predicts survival and early hematological toxicity. | Haematologica | 2026 | 42273943 | PubTator, text mining | PubMed |
| Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case-Control Study. | J Clin Med | 2026 | 42123142 | PubTator, text mining | PubMed |
| Multi-omics analysis identifies oxidative stress-related biomarkers and therapeutic targets linking periodontitis and ulcerative colitis via the oral-gut axis. | Front Immunol | 2026 | 42039174 | PubTator, text mining | PubMed |
| VE-cadherin NOT-gated CD93 CAR T cells discriminate between AML and healthy endothelial cells. | bioRxiv | 2026 | 41959197 | PubTator, text mining | PubMed |
| CD93-targeted resveratrol-loaded PLGA nanoparticles remodel CD8⁺ T cell metabolism through AIF-mediated oxidative phosphorylation to overcome lung cancer immunotherapy resistance. | J Nanobiotechnology | 2026 | 41832487 | PubTator, text mining | PubMed |
| Development and validation of a potency assay matrix for optimized and consistent manufacture of clinical mesenchymal stem/stromal cells. | Front Immunol | 2026 | 41798920 | PubTator, text mining | PubMed |
| Clinical, Prognostic, and Biological Features of High-Risk Cardiometabolic Phenotype: The REMODEL Study. | MedComm (2020) | 2026 | 41768368 | PubTator, text mining | PubMed |
| Comparative cross-methodological analysis of the IDH-wildtype glioblastoma tumor microenvironment. | J Cancer Res Clin Oncol | 2026 | 41762316 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/22918/papers